Inhibition of iNOS activity enhances the anti-tumor effects of alpha-galactosylceramide in established murine cancer model

Oncotarget

Volumn 6, Issue 39, 2015, Pages 41863-41874

  Ito, Hiroyasu ^a   Ando, Tatsuya ^a   Seishima, Mitsuru ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alpha garactosylceramide; Cancer immunotherapy; Induced nitric oxide synthase; MDSC; Tumor antigen specific immune response

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CXCL9 CHEMOKINE; FAS LIGAND; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G) NITROARGININE METHYL ESTER; TUMOR ANTIGEN; ALPHA-GALACTOSYLCERAMIDE; ANTINEOPLASTIC AGENT; CYTOKINE; ENZYME INHIBITOR; GALACTOSYLCERAMIDE; NOS2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRONCHOALVEOLAR LAVAGE FLUID; CANCER INHIBITION; CANCER MODEL; CCL2 GENE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CXCL9 GENE; ENZYME ACTIVITY; ENZYME INHIBITION; FASL GENE; GENE EXPRESSION; IFN GAMMA GENE; IMMUNE RESPONSE; IN VIVO STUDY; INHIBITION KINETICS; INOS GENE; LUNG METASTASIS; MALE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIMARY TUMOR; SUPPRESSOR CELL; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG NEOPLASMS; METABOLISM; SECONDARY; TIME FACTOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRONCHOALVEOLAR LAVAGE FLUID; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; ENZYME INHIBITORS; GALACTOSYLCERAMIDES; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE TYPE II; TIME FACTORS;

EID: 84951731017     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6172     Document Type: Article

References (36)

1. Terabe M and Berzofsky JA. The immunoregulatory role of type I and type II NKT cells in cancer and other diseases. Cancer immunology, immunotherapy: CII. 2014; 63:199-213.
2. Ito H, Ando K, Nakayama T, Taniguchi M, Ezaki T, Saito K, Takemura M, Sekikawa K, Imawari M, Seishima M and Moriwaki H. Role of Valpha 14 NKT cells in the development of impaired liver regeneration in vivo. Hepatology. 2003; 38:1116-1124.
3. Ito H, Koide N, Hassan F, Islam S, Tumurkhuu G, Mori I, Yoshida T, Kakumu S, Moriwaki H and Yokochi T. Lethal endotoxic shock using alpha-galactosylceramide sensitization as a new experimental model of septic shock. Lab Invest. 2006; 86:254-261.
4. Ito H, Ando K, Ishikawa T, Nakayama T, Taniguchi M, Saito K, Imawari M, Moriwaki H, Yokochi T, Kakumu S and Seishima M. Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific CTL: activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance. International immunology. 2008; 20:869-879.
5. Fuji N, Ueda Y, Fujiwara H, Toh T, Yoshimura T and Yamagishi H. Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver. Clinical cancer research: an official journal of the American Association for Cancer Research. 2000; 6:3380-3387.
6. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, Yagita H and Godfrey DI. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood. 2002; 99:1259-1266.
7. Nakui M, Ohta A, Sekimoto M, Sato M, Iwakabe K, Yahata T, Kitamura H, Koda T, Kawano T, Makuuchi H, Taniguchi M and Nishimura T. Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells. Clinical & experimental metastasis. 2000; 18:147-153.
8. Nishio S, Yamada N, Ohyama H, Yamanegi K, Nakasho K, Hata M, Nakamura Y, Fukunaga S, Futani H, Yoshiya S, Ueda H, Taniguchi M, Okamura H and Terada N. Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alphagalactosylceramide and interleukin-18. Cancer science. 2008; 99:113-120.
9. Xu W, Liu LZ, Loizidou M, Ahmed M and Charles IG. The role of nitric oxide in cancer. Cell Res. 2002; 12:311-320.
10. Lagares-Garcia JA, Moore RA, Collier B, Heggere M, Diaz F and Qian F. Nitric oxide synthase as a marker in colorectal carcinoma. Am Surg. 2001; 67:709-713.
11. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG and Moncada S. Nitric oxide synthase activity in human breast cancer. Br J Cancer. 1995; 72:41-44.
12. Ochoa AC, Zea AH, Hernandez C and Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007; 13:721s-726s.
13. Parekh VV, Wu L, Olivares-Villagomez D, Wilson KT and Van Kaer L. Activated invariant NKT cells control central nervous system autoimmunity in a mechanism that involves myeloid-derived suppressor cells. J Immunol. 2013; 190:1948-1960.
14. Ito H, Koide N, Morikawa A, Hassan F, Islam S, Tumurkhuu G, Mori I, Yoshida T, Kakumu S, Moriwaki H and Yokochi T. Augmentation of lipopolysaccharide-induced nitric oxide production by alpha-galactosylceramide in mouse peritoneal cells. J Endotoxin Res. 2005; 11:213-219.
15. Ohtaki H, Ito H, Ando K, Ishikawa T, Saito K, Imawari M, Yokochi T, Moriwaki H and Seishima M. Valpha14 NKT cells activated by alpha-galactosylceramide augment lipopolysaccharide-induced nitric oxide production in mouse intra-hepatic lymphocytes. Biochemical and biophysical research communications. 2009; 378:579-583.
16. Ji Z, Fan Z, Zhang Y, Yu R, Yang H, Zhou C, Luo J and Ke ZJ. Thiamine deficiency promotes T cell infiltration in experimental autoimmune encephalomyelitis: the involvement of CCL2. J Immunol. 2014; 193:2157-2167.
17. Ochiai E, Sa Q, Brogli M, Kudo T, Wang X, Dubey JP and Suzuki Y. CXCL9 is important for recruiting immune T cells into the brain and inducing an accumulation of the T cells to the areas of tachyzoite proliferation to prevent reactivation of chronic cerebral infection with Toxoplasma gondii. Am J Pathol. 2015; 185:314-324.
18. Colombo MP and Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002; 13:155-168.
19. Ando T, Ito H, Arioka Y, Ogiso H and Seishima M. Combination therapy with alpha-galactosylceramide and a Toll-like receptor agonist exerts an augmented suppressive effect on lung tumor metastasis in a mouse model. Oncology reports. 2015; 33:826-832.
20. Macho-Fernandez E, Cruz LJ, Ghinnagow R, Fontaine J, Bialecki E, Frisch B, Trottein F and Faveeuw C. Targeted delivery of alpha-galactosylceramide to CD8alpha+ dendritic cells optimizes type I NKT cell-based antitumor responses. J Immunol. 2014; 193:961-969.
21. Nicol AJ, Tazbirkova A and Nieda M. Comparison of clinical and immunological effects of intravenous and intradermal administration of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells. Clin Cancer Res. 2011; 17:5140-5151.
22. Jeong YH, Kim Y, Song H, Chung YS, Park SB and Kim HS. Anti-inflammatory effects of alpha-galactosylceramide analogs in activated microglia: involvement of the p38 MAPK signaling pathway. PloS one. 2014; 9:e87030.
23. Riquelme P, Tomiuk S, Kammler A, Fandrich F, Schlitt HJ, Geissler EK and Hutchinson JA. IFN-gamma-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Mol Ther. 2013; 21:409-422.
24. McNamara MJ, Kasiewicz MJ, Linch SN, Dubay C and Redmond WL. Common gamma chain (gammac) cytokines differentially potentiate TNFR family signaling in antigenactivated CD8(+) T cells. J Immunother Cancer. 2014; 2:28.
25. Ito H, Ando T, Arioka Y, Saito K and Seishima M. Inhibition of indoleamine 2, 3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model. Immunology. 2015; 144:621-630.
26. Ramirez-Montagut T, Chow A, Kochman AA, Smith OM, Suh D, Sindhi H, Lu S, Borsotti C, Grubin J, Patel N, Terwey TH, Kim TD, Heller G, Murphy GF, Liu C, Alpdogan O, et al. IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease. J Immunol. 2007; 179:1669-1680.
27. Su MW, Pyarajan S, Chang JH, Yu CL, Jin YJ, Stierhof YD, Walden P and BurakoffSJ. Fratricide of CD8+ cytotoxic T lymphocytes is dependent on cellular activation and perforin-mediated killing. Eur J Immunol. 2004; 34:2459-2470.
28. Khaled YS, Ammori BJ and Elkord E. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol. 2013; 91:493-502.
29. Ostrand-Rosenberg S and Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009; 182:4499-4506.
30. Zhang Y, Bi Y, Yang H, Chen X, Liu H, Lu Y, Zhang Z, Liao J, Yang S, Chu Y, Yang R and Liu G. mTOR limits the recruitment of CD11b+Gr1+Ly6Chigh myeloid-derived suppressor cells in protecting against murine immunological hepatic injury. J Leukoc Biol. 2014; 95:961-970.
31. Liu G, Bi Y, Wang R, Yang H, Zhang Y, Wang X, Liu H, Lu Y, Zhang Z, Chen W, Chu Y and Yang R. Targeting S1P1 receptor protects against murine immunological hepatic injury through myeloid-derived suppressor cells. J Immunol. 2014; 192:3068-3079.
32. Ito H, Ando T, Ogiso H, Arioka Y and Seishima M. Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice. Cancer immunology, immunotherapy: CII. 2015; 64:429-436.
33. Iwamoto N, Ito H, Ando K, Ishikawa T, Hara A, Taguchi A, Saito K, Takemura M, Imawari M, Moriwaki H and Seishima M. Upregulation of indoleamine 2, 3-dioxygenase in hepatocyte during acute hepatitis caused by hepatitis B virus-specific cytotoxic T lymphocytes in vivo. Liver international: official journal of the International Association for the Study of the Liver. 2009; 29:277-283.
34. Elcombe SE, Naqvi S, Van Den Bosch MW, MacKenzie KF, Cianfanelli F, Brown GD and Arthur JS. Dectin-1 regulates IL-10 production via a MSK1/2 and CREB dependent pathway and promotes the induction of regulatory macrophage markers. PloS one. 2013; 8:e60086.
35. Ito H, Ando T, Ando K, Ishikawa T, Saito K, Moriwaki H and Seishima M. Induction of HBsAg-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2, 3-dioxygenase activity. Immunology. 2014; 142:614-23.
36. Ito H, Ando K, Ishikawa T, Saito K, Takemura M, Imawari M, Moriwaki H and Seishima M. Role of TNFalpha produced by nonantigen-specific cells in a fulminant hepatitis mouse model. J Immunol. 2009; 182:391-397.